Literature DB >> 11190801

Use of the activated partial thromboplastin time for heparin monitoring.

M A Smythe1, J M Koerber, S J Westley, S N Nowak, R L Begle, M Balasubramaniam, J C Mattson.   

Abstract

The objectives of the present study were to evaluate the relationship between heparin concentration and activated partial thromboplastin time (aPTT) results, define a heparin concentration-derived therapeutic range for each aPTT instrument, compare aPTT- and heparin concentration-guided dosage adjustment decisions, and compare laboratory- and bedside aPTT-guided decisions. In phase 1, 102 blood samples were analyzed for bedside and laboratory aPTTs and heparin concentration (used to establish aPTT therapeutic range). In phase 2, 100 samples were analyzed in the same manner. Correlations for aPTT compared with heparin ranged from 0.36 to 0.82. Dosage adjustment decisions guided by the aPTT agreed with those based on heparin concentration 63% to 80% of the time. Laboratory and bedside aPTT dosage adjustment decisions agreed 59% to 68% of the time. The correlation of aPTT with heparin concentration and agreement between aPTT- and heparin-guided decisions vary with the aPTT instrument. Decisions guided by laboratory aPTT results often disagree with decisions guided by bedside aPTT results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11190801     DOI: 10.1309/N7RA-D6XN-9EQX-ABJ9

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

Review 1.  Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism.

Authors:  Maureen A Smythe; Jennifer Priziola; Paul P Dobesh; Diane Wirth; Adam Cuker; Ann K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

2.  First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects.

Authors:  Rui Chen; Xiaoduo Guan; Pei Hu; Yanli Dong; Yi Zhu; Tengfei Zhang; Jianjun Zou; Shuyang Zhang
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

3.  Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach.

Authors:  Ian A Scott; Nazanin Falconer; Stephen Canaris; Oscar Bonilla; Sven Marxen; Aaron Van Garderen; Michael Barras; Ahmad Abdel-Hafez
Journal:  Interact J Med Res       Date:  2022-09-19

4.  First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.

Authors:  Vidya Perera; Joseph M Luettgen; Zhaoqing Wang; Charles E Frost; Cynthia Yones; Cesare Russo; John Lee; Yue Zhao; Frank P LaCreta; Xuewen Ma; Robert M Knabb; Dietmar Seiffert; Mary DeSouza; Pierre Mugnier; Brenda Cirincione; Takayo Ueno; Robert J A Frost
Journal:  Br J Clin Pharmacol       Date:  2018-03-05       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.